Vildagliptin and pioglitazone hydrochloride

Vildagliptin and pioglitazone hydrochloride
VILDIABATE PIO  are two prescription medications that are often used together to treat type 2 diabetes.
Vildagliptin is a medication known as a dipeptidyl peptidase-4 (DPP-4) inhibitor. VILDIABATE PIO works by blocking the action of an enzyme in the body that breaks down incretin hormones, which help to regulate blood sugar levels. By inhibiting the breakdown of incretin hormones, vildagliptin helps to increase insulin secretion and reduce glucose production in the liver.
Pioglitazone hydrochloride is a medication known as a thiazolidinedione (TZD) or glitazone. VILDIABATE PIO works by increasing the sensitivity of cells in the body to insulin, which helps to improve blood sugar control.
Together,  VILDIABATE PIO can provide a more comprehensive approach to managing type 2 diabetes by addressing both the secretion of insulin and the body's sensitivity to it.
It is important to note that both medications can have potential side effects. Common side effects of vildagliptin include headache, nausea, and upper respiratory tract infection. Pioglitazone hydrochloride can cause weight gain, fluid retention, and an increased risk of bone fractures.
VILDIABATE PIO with any prescription medication, it is important to follow the dosage and scheduling instructions provided by your healthcare provider, and to report any side effects or concerns to them.
For further information please contact:
info@sterispharma.com